Non-opioid medications for the relief of chronic breathlessness: current evidence

References

• Bausewein C, Currow DC, Johnson MJ. Palliative care in respiratory medicine. ERS Monograph. 2016. DOI:10.1183/2312508X.erm7316.
   Google Scholar
• Peiffer C, Poline JB, Thivard L, et al. Neural substrates for the perception of acutelyinduced dyspnea. Am J Respir Crit Care Med. 2001;163:951–957.
   PubMed Web of Science ®Google Scholar
• Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol. 2002;88:1500–1511.
   PubMed Web of Science ®Google Scholar
• VonLeupoldt A, Sommer T, Kegat S, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med. 2008;177:1026–1032.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Simpson MIJ, Currow DC, et al. Magnetoencephalography to investigate central perception of exercise-induced breathlessness in people with chronic lung disease: a feasibility pilot. BMJ Open. 2015;5:e007535. DOI:10.1136/bmjopen-2014-007535
   PubMed Web of Science ®Google Scholar
• Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J. 2009;33(4):771–777.
   PubMed Web of Science ®Google Scholar
• Feldman JL, Mitchell GS, Nattie EE. Breathing: rhythmicity, plasticity, chemosensitivity. Annu Rev Neurosci. 2003;26:239–266.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Bland JM, Gahbauer EA, et al. Breathlessness in elderly adults during the last year of life sufficient to restrict activity: prevalence, pattern, and associated factors. J Am Geriatr Soc. 2016;64(1):73–80.
   PubMed Web of Science ®Google Scholar
• Neuman A, Gunnbjornsdottir M, Tunsater A, et al. Dyspnea in relation to symptoms of anxiety and depression: a prospective population study. Respir Med. 2006;100(10):1843–1849.
   PubMed Web of Science ®Google Scholar
• Currow DC, Abernethy AP, Allcroft P, et al. The need to research refractory breathlessness. Eur Respir J. 2016;47:342–343.
   PubMed Web of Science ®Google Scholar
• Currow DC, Johnson MJ. Distilling the essence of breathlessness - the first vital symptom. Eur Respir J. 2015;45:1526–1528. DOI:10.1183/09031936.00030115
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Currow DC. Chronic refractory breathlessness is a distinct clinical syndrome. Curr Opin Support Palliat Care. 2015 Sep;9(3):203–205.
   PubMed Web of Science ®Google Scholar
• Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445.
   PubMed Web of Science ®Google Scholar
• Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014 Aug;44(2):332–340. Epub 2014 Apr 17. DOI:10.1183/09031936.00008014.
   PubMed Web of Science ®Google Scholar
• Allcroft P, Margitanovic V, Greene A, et al. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. J Palliat Med. 2013 Jul;16(7):7414.
   Web of Science ®Google Scholar
• Gomutbutra P, O’Riordan DL, Pantilat SZ. Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care. J Pain Symptom Manage. 2013;45:885e891.
   Web of Science ®Google Scholar
• Mercadante S, Porzio G, Valle A, et al. Palliative sedation in patients with advanced cancer followed at home: a prospective study. J Pain Symptom Manage. 2014;47:860–866.
   PubMed Web of Science ®Google Scholar
• Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;(Issue 10):Art.No.:CD007354. DOI:10.1002/14651858.CD007354.pub3.
   PubMed Web of Science ®Google Scholar
• Clemens KE, Klaschik E. Dyspnoea associated with anxiety—symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients. Support Care Cancer. 2011;19:2027–2033.
   PubMed Web of Science ®Google Scholar
• Hardy J, Randall C, Pinkerton E, et al. A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease. Support Care Cancer. 2016;24:3069.
   PubMed Web of Science ®Google Scholar
• Argyropoulou P, Patakas D, Koukou A, et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration. 1993;60(4):216–220.
   PubMed Web of Science ®Google Scholar
• Singh NP, Despars JA, Stansbury DW, et al. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest. 1993;103(3):800–804.
   PubMed Web of Science ®Google Scholar
• Peoples AR, Bushunow PW, Garland SN, et al. Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomised placebo-controlled URCC CCOP study. Support Care Cancer. 2016 Mar; 24(3):1339–1347. DOI:10.1007/s00520-015-2903-6.
   PubMed Web of Science ®Google Scholar
• Gordon GH, Michiels TM, Mahutte CK, et al. Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease. Psychiatry Res. 1985;15:25–32.
   PubMed Web of Science ®Google Scholar
• Light RW, Merrill EJ, Despars J, et al. Mutalipassi LR doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(7):1377–1380.
   PubMedGoogle Scholar
• Borson S, McDonald GJ, Gayle T, et al. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992 May;33(2):190–201.
   PubMed Web of Science ®Google Scholar
• Grove A, Lipworth BJ, Ingram CG, et al. A comparison of the effects of prednisolone and mianserin on ventilatory, exercise and psychometric parameters in patients with chronic obstructive pulmonary disease. Eur J Clin Pharmacol. 1995;48(1):13–18.
   PubMed Web of Science ®Google Scholar
• Dale ET, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002;23(5):442–447.
   Web of Science ®Google Scholar
• Lacasse Y, Beaudoin L, Rousseau L, et al. Randomised trial of paroxetine in endstage COPD. Monaldi Arch Chest Dis. 2004 Jul, Sep;61(3):1407.
   Google Scholar
• Eiser N, Harte R, Spiros K, et al. Effect of treating depression on quality of life and exercise tolerance in severe COPD. COPD. 2005 Jun;2(2):23341.
   Google Scholar
• Alexopoulos GS, Kiosses DN, Sirey JA, et al. Untangling therapeutic ingredients of a personalized intervention for patients with depression and severe COPD (PID-C). Am J Geriatr Psychiatry. 2014 Nov;22(11):1316–1324.
   PubMed Web of Science ®Google Scholar
• Momtaz OM, Rabei SM, Tawfike NR, et al. Effect of treatment of depression and anxietyon physiological state of severe COPD patients Egyptian. J Chest Dis Tubercul. 2015;64:29–34.
   Google Scholar
• Stark RD, Gambles SA, Lewis JA. Methods to assess breathlessness in healthy subjects: a critical evaluation and application to analyse the acute effects of diazepam and promethazine on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide. Clin Sci. 1981;61:429–439.
   PubMed Web of Science ®Google Scholar
• Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. BMJ. 1981;283:343–346.
   PubMed Web of Science ®Google Scholar
• O’Neill PA, Morton PB, Stark RD. Chlorpromazine-a specific effect on breathlessness? Br J Clin Pharmac. 1985;19:793–797.
   PubMed Web of Science ®Google Scholar
• Rice KL, Kronenberg RS, Hedemark LL, et al. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest. 1987;81:287–292.
   PubMedGoogle Scholar
• Light RW, Stansbury DW, Webster JS. Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest. 1996;109:975–981.
   PubMed Web of Science ®Google Scholar
• Nishino T, Ide T, Sudo T, et al. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med. 2000;161:1963–1967.
   PubMed Web of Science ®Google Scholar
• Minowa Y, Ide T, Nishino T. Effects of inhaled furosemide on CO2 ventilatory responsiveness in humans. Pulm Pharmacol Ther. 2002;15:363–368.
   PubMed Web of Science ®Google Scholar
• Stone P, Rix E. Nebulized furosemide for dyspnea in terminal cancer patients. J Pain Symptom Manage. 2002 Sep;24(3):274–275.
   PubMed Web of Science ®Google Scholar
• Ong KC, Kor AC, Chong WF, et al. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1028–1033.
   PubMed Web of Science ®Google Scholar
• Moosavi SH, Binks AP, Lansinga RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol. 2007;156:1–8.
   PubMed Web of Science ®Google Scholar
• Laveneziana P, Galarducci A, Binazzi B, et al. Inhaled furosemide does not alleviate respiratory effort during flow-limited exercise in healthy subjects. Pulm Pharmacol Ther. 2008;21:196–200.
   PubMed Web of Science ®Google Scholar
• Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax. 2008;63:606–613.
   PubMed Web of Science ®Google Scholar
• Wilcock A, Walton A, Manderson C, et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax. 2008 Oct;63(10):872–875. Epub 2008 Apr 11. DOI:10.1136/thx.2007.091538.
   PubMed Web of Science ®Google Scholar
• Sheikh Motahar Vahedi H, Mahshidfar B, Rabiee H, et al. The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomised controlled clinical trial. Respir Care. 2013;58(11):1873–1877.
   PubMed Web of Science ®Google Scholar
• Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol. 1989;25(Suppl 1):21–24.
   PubMedGoogle Scholar
• Terkawi AS, Mavridis D, Flood P, et al. Does ondansetron modify sympathectomy due to subarachnoid anesthesia? Meta-analysis, meta-regression, and trial sequential analysis. Anesthesiology. 2016 Apr;124(4):846–869. DOI:10.1097/ALN.0000000000001039.
   PubMed Web of Science ®Google Scholar
• Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet. 2000 Mar 4;355(9206):792–797.
   PubMed Web of Science ®Google Scholar
• Martinez JA, Rocha FS, Sobrani E, et al. Effects of ondansetron on respiratory pattern and sensation of experimentally induced dyspnea. Sao Paulo Med J. 2002 Sep 2;120(5):141–145.
   PubMedGoogle Scholar
• Smoller JW, Pollack MH, Systrom D, et al. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998;39:24–29.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Molina J, Quintano JA, et al. Factors associated with depression and severe depression in patients with COPD. Respir Med. 2014;108:1615e1625.
   Web of Science ®Google Scholar
• Borges-Santos E, Takashi Wadaa J, Marques Da Silva C, et al. Anxiety and depression are related to dyspnea and clinical control butnot with thoracoabdominal mechanics in patients with COPD. Respir Physiol Neurobiol. 2015;210:1–6.
   PubMed Web of Science ®Google Scholar
• Papp LA, Weiss JR, Greenberg HE, et al. Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. Am J Psychiatry. 1995 Oct;152(10):1531.
   PubMed Web of Science ®Google Scholar
• Usmani ZA, Carson KV, Cheng JN, et al. Pharmacological interventions for the treatment of anxiety disorders in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;11:Art. No.: CD008483. DOI:10.1002/14651858.CD008483.pub2
   PubMed Web of Science ®Google Scholar
• Watts GJ, Clark K, Agar M, et al. Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness. BMJ Open. 2016;6:e013177. DOI:10.1136/bmjopen-2016-013177
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FER, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65:459–466.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473.
   PubMed Web of Science ®Google Scholar
• Pickering EE, Semple SJ, Nazir MS, et al. Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety. Chron Respir Dis. 2011;8(2):109–118.
   PubMed Web of Science ®Google Scholar
• Sudo T, Hayashi F, Nishino T. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am J Respir Crit Care Med. 2000;162:971–975.
   PubMed Web of Science ®Google Scholar
• Hinckley JB. Inhaled furosemide in the treatment of acute exacerbations of asthma. Acad Emerg Med. 2000 Oct;7(10):1167.
   PubMedGoogle Scholar
• Newton PJ, Davidson PM, Krum H, et al. The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure. Lung Circ. 2012;21:260–266.
   PubMed Web of Science ®Google Scholar
• Shimoyama N, Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage. 2002;23:73–76.
   PubMed Web of Science ®Google Scholar
• Kohara H, Ueoka H, Aoe K, et al. Effect of nebulized furosemidein terminally Ill cancer patients with dyspnea. J Pain Symptom Manage. 2003;26:962–967.
   PubMed Web of Science ®Google Scholar
• Khan SY, O’Driscoll BR. Is nebulized saline a placebo in COPD? BMC Pulm Med. 2004;4:9. DOI:10.1186/1471-2466-4-9
   PubMedGoogle Scholar
• Li SY, Li JS, Wang MH, et al. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomised, controlled study. BMC Complement Altern Med. 2012 Oct 29;12:197. DOI:10.1186/1472-6882-12-197.
   PubMed Web of Science ®Google Scholar
• Wang M, Li J, Li S, et al. Effects of comprehensive therapy based on traditional Chinese medicine patterns on older patients with chronic obstructive pulmonary disease: a subgroup analysis from a four-center, randomised, controlled study. Front Med. 2014 Sep;8(3):368–375. Epub 2014 Sep 9. DOI:10.1007/s11684-014-0360-0.
   PubMed Web of Science ®Google Scholar
• Disler RT, Green A, Luckett T, et al. Experience of advanced chronic obstructive pulmonary disease: metasynthesis of qualitative research. J Pain Symptom Manage. 2014 Dec;48(6):1182–1199.
   PubMed Web of Science ®Google Scholar
• Yu DS, Lee DT, Kwong AN, et al. Living with chronic heart failure: a review of qualitative studies of older people. J Adv Nurs. 2008 Mar;61(5):474–483.
   PubMed Web of Science ®Google Scholar
• Pesola GR, Ahsan H. Dyspnea as an independent predictor of mortality. Clin Respir J. 2016;10(2):142–152.
   PubMed Web of Science ®Google Scholar
• Jones PW, Adamek L, Nadeau G, et al. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013 Sep;42(3):647–654.
   PubMed Web of Science ®Google Scholar
• Niska R, Bhuiya F, Xu J. National hospital ambulatory medical care survey: 2007 emergency department summary. Natl Health Stat Rep. 2010;26:1–31.
   PubMedGoogle Scholar